Dhwani Patel

Results-driven professional with 5 years of experience in the pharmaceutical industry, focusing on various therapeutic categories and drug products. Integrates scientific expertise with commercial strategies to improve global patient outcomes. Delivers impactful results through collaboration and effective communication.

• Scientist, Amneal Pharmaceuticals, Piscataway, NJ, Oct 2015- Jan 2021
• Analytical Scientist, Bristol-Myers Squibb, New Brunswick, NJ, Dec 2014- Oct 2015
• Chemist 3, Merck & Co., Rahway, NJ, Jun 2014 - Sep 2014
• Analytical Scientist, Novartis Consumer Health, Lincoln, NE, Feb 2014 - Jun 2014
• Chemist, Cargill, Blair, NE, Dec 2013 - Jan 2014

• Launch Readiness for Biosimilars, Performed secondary market research to study disease landscape, current and evolving market trends for biosimilars. Analyzed the market size and opportunity to evaluate the key unmet needs, barriers to entry, critical success factors and key unmet needs in the market. Assessed the current market opportunities to build the target product portfolio for different therapeutic areas along with the potential market size, key competitors along with their pipeline products. Conducted secondary market research using market research platforms such as Data monitor, IPD analytics, KOL interviews etc. to gather deeper market insights to build a launch roadmap for the DRL pipeline. Mapped the key strategic KOLs, influencers and gatekeepers to gain deeper insights and identify the critical levers or constraints to drug usage. Explored patient services platforms such as Cardinal Health to build patient services and an engagement strategy to ensure faster market penetration post launch. Identified and built a profile for key customer segments - specialists, HCPs, caregivers, care communities etc. to direct a better approach for marketing communications and promotional strategy.
• Launch of Phase 3 Hematology Candidate, Evaluated the NCCN treatment guidelines to understand the current approach to treatment for different stages of the disease and analyze the different drug MOAs/classes used for each stage of the disease. Built competitive landscape and scenario analysis to determine product positioning vs. competitors. Summarized the key clinical trials, current and expected data, KOL and HCP insights, prelaunch initiatives and a SWOT analysis for the competitors. Conducted a client workshop across functional areas both locally and globally to understand the local market landscape and build strategic recommendations for a successful product launch. Conducted primary market research, KOL interviews and secondary market research to determine the key drivers of prescribing behaviors across target segments. Identified the critical levers for superior clinical differentiation within the product/market landscape.
• Launch of Phase 3 Drug for Alopecia (EU and Emerging markets), Developed the market landscape for Alopecia including the existing products in the market, the pipeline products and their different clinical trial stages. Evaluated the market opportunity based on disease severity, unmet needs, current treatment gaps and disease burden. Analyzed and generated critical insights about Alopecia alternative treatments, key drug classes in use and the major determinants of HCP prescribing behavior. Analyzed and generated critical insights about the Alopecia competitive scenario and launch timelines across global markets, UK, Spain, Italy, France, Brazil, UAE, Taiwan etc. Built key HCP and patient segments with their key characteristics and features that would be major influencers/drivers of drug product uptake. Built a target product profile and a SWOT analysis for the drug product. Assessed the stakeholder landscape, clinical guidelines, market access policies to identify key gaps and challenges across the markets to achieve timely access to treatments. Developed a strategic imperative based on primary and secondary research, team brainstorming sessions and client meetings to shape a detailed action plan based on different launch phases of the drug to ensure a successful product uptake across the product life cycle in the market.